skip to Main Content

2021 Women's Venture Competition

The Women’s Venture Competition review committees are comprised of a combination of world-class life sciences industry professionals, investors and entrepreneurs from within the extensive network of the National Foundation for Cancer Research, the non-profit affiliate of the AIM-HI Accelerator Fund.

The winning company of 2021 Women’s Venture Competition will receive a total of $1 million in investment from AIM-HI and co-investors, subject to due diligence and negotiation. These funds will serve as seed money for proof of concept and proof of value on the path to clinical trials, and eventually, to new effective therapeutics and diagnostics that will eventually save patients’ lives.

Ready to do more? DONATE NOW and help us double the impact for women scientist-entrepreneurs who are creating life-saving oncology innovations!

Judging Committee:

Monica Bertagnolli, M.D. | Co-Chair

Monica Bertagnolli, M.D. | Co-Chair

Richard E. Wilson Professor of Surgery in the Field of Surgical Oncology, Harvard Medical School

Raju Kucherlapati, Ph.D. | Co-Chair

Raju Kucherlapati, Ph.D. | Co-Chair

Paul C. Cabot Professor of Genetics & Professor of Medicine, Harvard Medical School

Webster Cavenee, Ph.D.

Webster Cavenee, Ph.D.

Director of Strategic Alliances, Ludwig Institute for Cancer Research

Pamela Garzone, Ph.D.

Pamela Garzone, Ph.D.

Pharmaceutical Executive

Dimitra Georganopoulou, Ph.D.

Dimitra Georganopoulou, Ph.D.

Innovation Faculty, MIT linQ CATALYST

Scott Lippman, M.D.

Scott Lippman, M.D.

Director, Moores Cancer Center, UC San Diego Health

Tom Miller

Tom Miller

Founder & Managing Partner, GreyBird Ventures

Patty Obermaier

Patty Obermaier

Vice President, US Health and Life Sciences, Microsoft

Robert Tepper, M.D.

Robert Tepper, M.D.

Partner, Third Rock Ventures

Selection Committee:

Pamela Garzone, Ph.D. | Co-Chair

Pamela Garzone, Ph.D. | Co-Chair

Pharmaceutical Executive

Raju Kucherlapati, Ph.D. | Co-Chair

Raju Kucherlapati, Ph.D. | Co-Chair

Paul C. Cabot Professor of Genetics & Professor of Medicine, Harvard Medical School

Webster Cavenee, Ph.D.

Webster Cavenee, Ph.D.

Director of Strategic Alliances, Ludwig Institute for Cancer Research

Aleksandra Filipovic, M.D., Ph.D.

Aleksandra Filipovic, M.D., Ph.D.

Head of Oncology, PureTech Health

Dimitra Georganopoulou, Ph.D.

Dimitra Georganopoulou, Ph.D.

Innovation Faculty, MIT linQ CATALYST

Scott Lippman, M.D.

Scott Lippman, M.D.

Director, Moores Cancer Center, UC San Diego Health

Michael Salgaller, Ph.D.

Michael Salgaller, Ph.D.

Supervisory Invention Development & Marketing Specialist, National Institutes of Health/National Cancer Institute

Thea Tlsty, Ph.D.

Thea Tlsty, Ph.D.

Professor of Pathology, University of California San Francisco

Michael Wang, M.D., Ph.D., MBA

Michael Wang, M.D., Ph.D., MBA

Chief Science Officer, AIM-HI Accelerator Fund

Investment Committee:

Jimmy Lu, J.D., MBA, Chair

Jimmy Lu, J.D., MBA, Chair

Managing Director, WI Harper Group

Dimitra Georganopoulou, Ph.D.

Dimitra Georganopoulou, Ph.D.

Innovation Faculty, MIT linQ CATALYST

Raju Kucherlapati, Ph.D.

Raju Kucherlapati, Ph.D.

Paul C. Cabot Professor of Genetics & Professor of Medicine, Harvard Medical School

Matt Tremblay, Ph.D.

Matt Tremblay, Ph.D.

Chief Operating Officer, Scripps Research

Michael Wang, M.D., Ph.D., MBA

Michael Wang, M.D., Ph.D., MBA

CSO, National Foundation for Cancer Research

Rose Wang, MBA

Rose Wang, MBA

Executive Advisor, AIM-HI Accelerator Fund

Yajun Xu, Ph.D.

Yajun Xu, Ph.D.

Managing Partner, Hongsen Capital

Back To Top